Cargando…
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human disease was used to test whether a STimulator of Interferon Genes (STING) agonist could reignite immunologically in...
Autores principales: | Jing, Weiqing, McAllister, Donna, Vonderhaar, Emily P., Palen, Katie, Riese, Matthew J., Gershan, Jill, Johnson, Bryon D., Dwinell, Michael B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489306/ https://www.ncbi.nlm.nih.gov/pubmed/31036082 http://dx.doi.org/10.1186/s40425-019-0573-5 |
Ejemplares similares
-
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer
por: Vonderhaar, Emily P., et al.
Publicado: (2021) -
2543 High concentrations of CXCL12 decrease pancreatic adenocarcinoma growth
por: Vonderhaar, Emily, et al.
Publicado: (2018) -
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models
por: Tsai, Susan, et al.
Publicado: (2018) -
E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells
por: Palen, Katie, et al.
Publicado: (2016) -
Adoptive cell therapy using PD-1(+) myeloma-reactive T cells eliminates established myeloma in mice
por: Jing, Weiqing, et al.
Publicado: (2017)